New structural insights reveal a clever new use of antibodies to treat and possibly prevent infections by on the of the world ...

Royalty Pharma has made another play in the autoimmune space, this time crowning Johnson & Johnson as the beneficiary. Royalty and J&J have agreed to co-fund the development of a chronic autoimmune ...

March 31 (Reuters) - Biotech firm Infinimmune said on Tuesday it has entered into a deal with Merck, that could be worth up ...

This biotech firm developing antibody therapies for rare diseases disclosed a significant insider sale amid rapid share price ...

In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed ...

Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million ...

Cancer treatment has long been haunted by the same problem: how do you strike dangerous cells without hitting healthy ones ...

This biotech innovator in antibody therapeutics reported a notable insider sale amid a year of dramatic share price gains.

Repeatedly elevated Epstein-Barr virus antibodies on serial blood tests may help distinguish multiple sclerosis from MOGAD ...

Researchers from The University of Texas MD Anderson Cancer Center have developed a first-in-class antibody that targets a ...

Antibody–drug conjugates (ADCs) represent one of the most transformative advances in precision oncology over the past two decades and are increasingly positioned to replace conventional chemotherapy ...